论文部分内容阅读
目的 探讨骨肉瘤组织中HSP_(70)和Survivin的表达及其临床意义。方法 应用免疫组化方法检测34例骨肉瘤病人的骨肉瘤组织和15例正常骨组织中HSP_(70)和Survivin的表达情况,综合分析临床病理指标。结果 34例骨肉瘤组织中HSP_(70)和Survivin的阳性表达率分别为88.2％和82.4％,而正常骨组织其表达率均为零。HSP_(70)和Survivin在低分化组和短生存组的骨肉瘤中,其阳性表达率明显高于高、中分化组和长生存组骨肉瘤。结论 检测HSP_(70)和Survivin为骨肉瘤恶性程度和预后的评估提供了一定的辅助参考指标。
Objective To investigate the expression of HSP70 (70) and Survivin in osteosarcoma and its clinical significance. Methods Immunohistochemistry was used to detect the expression of HSP70 and Survivin in 34 cases of osteosarcoma and 15 cases of normal bone tissue. The clinicopathological parameters were analyzed comprehensively. Results The positive expression rates of HSP70 and Survivin in 34 cases of osteosarcoma were 88.2% and 82.4% respectively, while those in normal bone tissues were all zero. The positive rates of HSP70 and Survivin in poorly differentiated and short-survival osteosarcoma groups were significantly higher than those in high, moderately differentiated and long-lived osteosarcoma groups. Conclusion The detection of HSP70 and Survivin provide some auxiliary reference for the evaluation of malignant degree and prognosis of osteosarcoma.